Boston Family Office LLC Has $892,000 Stock Holdings in Becton, Dickinson and Company $BDX

Boston Family Office LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 5,177 shares of the medical instruments supplier’s stock after selling 470 shares during the period. Boston Family Office LLC’s holdings in Becton, Dickinson and Company were worth $892,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Bill Few Associates Inc. lifted its stake in Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares during the period. Gilbert & Cook Inc. lifted its position in shares of Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after buying an additional 56 shares during the period. Mendel Money Management boosted its stake in Becton, Dickinson and Company by 2.6% in the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after buying an additional 58 shares in the last quarter. Plancorp LLC grew its position in Becton, Dickinson and Company by 4.1% in the first quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock valued at $343,000 after acquiring an additional 59 shares during the period. Finally, Moody National Bank Trust Division raised its stake in Becton, Dickinson and Company by 2.4% during the second quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock worth $445,000 after acquiring an additional 60 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 1,249 shares of company stock valued at $231,358. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group lowered their target price on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a report on Friday, November 7th. Piper Sandler decreased their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus price target of $203.27.

Becton, Dickinson and Company Price Performance

BDX opened at $191.88 on Tuesday. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company’s 50 day simple moving average is $187.60 and its 200-day simple moving average is $183.36. The stock has a market capitalization of $54.76 billion, a P/E ratio of 34.51, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion during the quarter. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.